Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III
Uložené v:
| Názov: | Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III |
|---|---|
| Autori: | Yang Liu, Steven Ho Man Lam, Giulio Francesco Romiti, Bi Huang, Yang Chen, Tze Fan Chao, Brian Olshansky, Kui Hong, Menno V. Huisman, Gregory Y. H. Lip |
| Zdroj: | J Thromb Thrombolysis Liu, Y, Lam, S H M, Romiti, G F, Huang, B, Chen, Y, Chao, T F, Olshansky, B, Hong, K, Huisman, M V, Lip, G Y H & GLORIA-AF Investigators 2025, 'Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III', Journal of Thrombosis and Thrombolysis, vol. 58, no. 2, pp. 165-177. https://doi.org/10.1007/s11239-025-03067-5 |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2025. |
| Rok vydania: | 2025 |
| Predmety: | Aged, 80 and over, Male, Atrial Fibrillation/drug therapy, Myocardial Infarction, Administration, Oral, Thromboembolism/prevention & control, Atrial fibrillation, Non-vitamin K antagonist oral anticoagulants (NOACs), Oral anticoagulant, Renal function, Vitamin K antagonists (VKA), Creatinine/blood, Middle Aged, Article, Hemorrhage/chemically induced, Humans, Female, Prospective Studies, Registries, Vitamin K/antagonists & inhibitors, Anticoagulants/adverse effects, Kidney/physiopathology, Aged |
| Popis: | Renal function, assessed by creatinine clearance (CrCl), affects the efficacy and safety of oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF). To investigate the association between CrCl and the risk of clinical adverse events and compare the safety profiles of vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Patients with newly diagnosed AF ( Graphical abstract |
| Druh dokumentu: | Article Other literature type |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1573-742X |
| DOI: | 10.1007/s11239-025-03067-5 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39924624 http://www.scopus.com/inward/record.url?scp=85217991158&partnerID=8YFLogxK https://vbn.aau.dk/ws/files/771126032/Liu_et_al._2025_._Renal_function_and_adverse_clinical_events_in_anticoagulated_patients_with_atrial_fibrillation_-_insights_from_the_GLORIA-AF_Registry_Phase_III.pdf https://doi.org/10.1007/s11239-025-03067-5 https://vbn.aau.dk/da/publications/2c7e57c1-1ba7-413d-b154-340ae1137c20 https://hdl.handle.net/11573/1733543 https://doi.org/10.1007/s11239-025-03067-5 |
| Rights: | CC BY |
| Prístupové číslo: | edsair.doi.dedup.....789b76cceb215de9c3b0a7a2ebfbc007 |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Renal function, assessed by creatinine clearance (CrCl), affects the efficacy and safety of oral anticoagulant (OAC) therapy in patients with atrial fibrillation (AF). To investigate the association between CrCl and the risk of clinical adverse events and compare the safety profiles of vitamin K antagonists (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Patients with newly diagnosed AF ( Graphical abstract |
|---|---|
| ISSN: | 1573742X |
| DOI: | 10.1007/s11239-025-03067-5 |